Salix Coronary Plaque vs AVIEW

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Artrya
VS
by Coreline Soft Co.

AI Verdict

Tool A, Salix Coronary Plaque, is highly specialized for in-depth analysis of coronary artery plaque and stenosis from CCTA scans, focusing on detailed plaque characterization. Tool B, AVIEW, offers a broader AI platform, providing comprehensive solutions for lung cancer and COPD detection and monitoring, in addition to coronary artery calcium scoring. While both tools perform cardiac CT analysis and calcium scoring, Tool A is a specialist in plaque morphology, whereas Tool B is a generalist with a strong pulmonary focus.

Choose Salix Coronary Plaque if…

Choose Salix Coronary Plaque if your primary need is a rapid, in-depth, and point-of-care assessment of coronary artery plaque characteristics and stenosis directly from CCTA scans. This tool is specifically designed for detailed quantification of atherosclerosis and identification of high-risk plaque features to support immediate diagnostic decisions in cardiology.

View Salix Coronary Plaque →

Choose AVIEW if…

Choose AVIEW if your institution requires a comprehensive AI platform for broad thoracic CT analysis, encompassing early detection and monitoring of lung cancer, COPD, and general cardiovascular risk through coronary artery calcium scoring. This solution is ideal for streamlining radiology workflows and managing longitudinal studies across multiple pulmonary and cardiac conditions.

View AVIEW →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Salix Coronary Plaque AVIEW
Pricing Subscription model Subscription; one-off payment
Deployment Cloud-based (Amazon Web Services), web-based software application Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
BAA Available Yes AI-estimated Unknown
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Salix Coronary Plaque

Tool A, Salix Coronary Plaque, emphasizes 'near real-time, point-of-care assessment' and is 'web-based software,' suggesting a highly streamlined and accessible user experience for immediate clinical utility. While Tool B offers broader deployment options, Tool A's focus on rapid, integrated workflow for its specific use case likely translates to superior end-user usability in a clinical setting.

Clinical Value

AVIEW

Tool B, AVIEW, offers broader clinical value by providing comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans. While Tool A specializes in detailed coronary plaque analysis, Tool B's multi-organ capabilities address a wider range of critical conditions, enhancing diagnostic precision across multiple specialties.

Pricing & Value

Salix Coronary Plaque

Tool A provides a clearer value proposition by explicitly linking its per-scan assessment model to a US CPT reimbursement rate of US$950 per assessment, offering a direct pathway for cost recovery and financial transparency. Tool B offers flexible pricing models (subscription, one-off) but lacks specific pricing details or direct ties to reimbursement, making its financial value less immediately transparent.

Enterprise Readiness

AVIEW

Tool B demonstrates superior enterprise readiness with explicit HIPAA compliance and a comprehensive suite of deployment options, including cloud-based, hybrid, local on dedicated hardware, and locally virtualized solutions. It also explicitly mentions workflow automation and integration with PACS/RIS/CIS, crucial for diverse enterprise IT infrastructures.

Innovation

Tie

Both tools demonstrate strong innovation in their respective domains. Tool A's ability to identify specific high-risk plaque features (e.g., low-attenuation plaque, napkin-ring sign) in near real-time for coronary artery disease is highly innovative for precise risk stratification. Tool B's comprehensive multi-organ approach, including advanced features like ILD pattern analysis and nodule matching for serial scans, also showcases significant innovation across a broader spectrum of conditions.

Support & Docs

AVIEW

Coreline Soft (Tool B) provides clear contact information for a dedicated Customer Service Team and has established regional corporations in Europe and North America, indicating structured support channels. Artrya (Tool A) offers general contact emails and a regional support site selector, but less specific detail on dedicated customer service teams or comprehensive documentation access.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Salix Coronary Plaque AVIEW
Name Salix Coronary Plaque AVIEW
Company Artrya Limited Coreline Soft Co.
Description FDA-cleared, AI-driven, web-based software that provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease. AI platform offering comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows.
Categories Cardiology AI Cardiology AI, Oncology AI, Radiology & Imaging AI
Specialties Cardiology, Radiology Cardiology, Pulmonology, Radiology
Key Features AI-enabled CCTA analysis, Near real-time, point-of-care assessment, Detection and quantification of coronary plaque (atherosclerosis), Identification of high-risk plaque features (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign), Stenosis assessment, Quantification of calcifications (calcium scoring), Integrated workflow management, Automated report generation (editable) AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score), Emphysema quantification and low attenuation area (LAA) analysis, Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification), Automated segmentation of lung lobes, airways, vessels, and coronary arteries, 3D visualizations and comprehensive PDF reports, Workflow automation and integration with PACS/RIS/CIS, Follow-up registration and nodule matching for serial CT scans, Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture)

Videos

Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and AVIEW.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Salix Coronary Plaque (Tool A) specializes in detailed coronary artery plaque and stenosis assessment from CCTA scans, including the identification of high-risk plaque features. AVIEW (Tool B) offers coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification) as part of a broader platform that also addresses lung conditions.
Salix Coronary Plaque (Tool A) is specifically focused on coronary artery disease. AVIEW (Tool B) provides comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and interstitial lung disease (ILD) pattern analysis from CT scans, in addition to its cardiac calcium scoring capabilities.
Salix Coronary Plaque (Tool A) operates on a per-scan assessment model, with a US CPT reimbursement rate of US$950 per assessment mentioned. AVIEW (Tool B) offers both subscription and one-off payment models, with pricing based on the number of installations or users.
Yes, Salix Coronary Plaque (Tool A) explicitly identifies high-risk plaque features such as low-attenuation plaque, spotty calcification, positive remodeling, and the napkin-ring sign. AVIEW (Tool B) focuses on quantifying coronary artery calcification and providing risk stratification based on CAC scores.
Salix Coronary Plaque (Tool A) is specifically designed to provide near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, with assessments available in less than 10 minutes. AVIEW (Tool B) does not explicitly state this feature for its cardiac capabilities.
AI Tool Finder
AI-powered search. Results may not be comprehensive.